

Five Prime Therapeutics, Inc. Investor Relations Department Two Corporate Dr, Suite 200 South San Francisco, CA 94080 United States

Visit IR website ☐ Sign-up for email alerts ☐

### NASDAQ: FPRX 1 Last Trade: 31.24 Trade Time: 4:00 PM ET Friday, June 23, 2017 -0.22 Change: (0.699%)Day Range 30.35 - 31.40 52-Week Range 27.01 - 60.98 Volume 560,380 Market Cap. 899.400 (\$M) Shares Out (M) 28.790

# **Company Profile**

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immunooncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... <u>(more)</u>

## **Stock Performance**



## Press Releases [View all]

Wednesday, June 21, 2017

Five Prime Therapeutics Announces Lewis T.

"Rusty" Williams Plans to Transition from
CEO to Executive Chairman of the Board in
2018

Monday, June 5, 2017

<u>Five Prime Therapeutics to Present at the</u>
Jefferies 2017 Global Healthcare Conference

Sunday, June 4, 2017

Five Prime Therapeutics Presents Initial
Clinical Trial Data from Phase 1/2 trial of
Cabiralizumab in Pigmented Villonodular
Synovitis (PVNS) at 2017 ASCO Annual
Meeting

Saturday, June 3, 2017

Five Prime Therapeutics Presents Updated

Data From Phase 1 Trial of Single-Agent
FPA144 at 2017 ASCO Annual Meeting

Monday, May 15, 2017
Five Prime Welcomes Garry Nicholson to
Board of Directors

### Events [View all]

There are no events to display at this time. Please check back later.

## Financials [View all]

First Quarter Financial Results

Friday, February 24, 2017 Annual Report (10-K)

Friday, March 31, 2017

<u>Definitive Proxy Statement</u>

Friday, May 5, 2017
Quarterly Report (10-Q)

Friday, November 4, 2016 Quarterly Report (10-Q)

Friday, August 5, 2016
Quarterly Report (10-Q)



<sup>&</sup>lt;sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.